HCM
KYNB

Highbridge Capital Management’s Kyntra Bio KYNB Stock Holding History

Highbridge Capital Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-6,411
Closed -$3.51M – 1568
2015
Q3 		$3.51M Buy
+6,411
New +$3.88M 0.05% 390

Other funds holding KYNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Highbridge Capital Management's KYNB Position: Q4 2015 in Review

Highbridge Capital Management sold out of Kyntra Bio (KYNB) in Q4 2015, closing a stake of 6,411 shares — an estimated $3.51M sold.

Highbridge Capital Management first reported a position in KYNB in Q3 2015 and held it in 1 quarter. The position peaked at $3.51M in Q3 2015. 134 funds tracked by Wall St. Rank hold KYNB as of Q4 2015.

  • Highbridge Capital Management reported no remaining Kyntra Bio position as of Q4 2015 after selling out during the quarter.
  • Highbridge Capital Management sold 6,411 Kyntra Bio shares in Q4 2015, an estimated $3.51M.
  • Highbridge Capital Management first reported a position in Kyntra Bio in Q3 2015 and held it in 1 quarter.
  • Highbridge Capital Management's Kyntra Bio position peaked at $3.51M in Q3 2015.
  • 134 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2015.

Based on Highbridge Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.